Immunotherapy. Angiogenesis. Precision Medicine. Genomic Testing.
Biomarkers. Therapeutic Antibody Engineering. CAR T Cell Therapy.
When the Asian Fund for Cancer Research (AFCR) was founded one and half decades ago, many of these words did not exist or were never used in relation to cancer.
But because friends like you so generously supported cancer research and the science community’s commitment to breakthrough cancer discovery, these words now have real meaning for people facing a cancer diagnosis. They mean the promise of a healthier future.
That’s why, AFCR wants to re-affirm our vision and determination with you—our most important partners in this journey.
Many of the most promising cancer-fighting clinical technologies of this new era were, ten years ago, but only projects in the labs of forward-looking scientists. Yet look at the impact they’re having now!
Imagine what your contribution to research at this moment will make possible for cancer patients ten years into the future. Lives saved, families together and friendships continued.
You’ll help us fund the most promising and innovative investigations, resulting in new and more effective drugs and therapies. Your generosity will also help advance the development of new and improved methods to detect cancer in the earliest possible stages.
In 2020 and beyond, your support will be translated into research areas including but not limited to:
- Multi-functional Antibodies to Crack the Toughest Therapeutic Challenges: more refined therapies for large patient groups that do not respond to current cancer therapies or who suffer relapses
- Bridging Research from Academia to Cancer Entrepreneurship (BRACE): AFCR’s BRACE Award recognizes, honors and highlights the scientific innovation required to translate scientific breakthroughs being made in academic research laboratories into new approaches to diagnosing and treating cancer.
- Modernize Botanical Medicines into internationally recognized research and medicine: YIV-906 cancer drug can potentiate anti-tumor activity for immunotherapy, chemotherapy and radiation therapies and could become the backbone drug for future cancer regimens.
- Collaborative Drug Development Program between AFCR and its partner, U.S. National Foundation for Cancer Research: design and synthesis of next generation inhibitors to a major cancer growth pathway in many cancer types while eliminating potential for drug-resistance in patients.
Novel research programs like these can result in game-changing, life-saving diagnoses, treatments, prevention, and cures for cancers. As you know, cancer research is a long term commitment. It takes time to explore novel ideas, develop them into therapies, and test their efficacy. And it requires a dedicated team and shared visionar, including friends like you.
That’s why we need your valued and continued support. Please send your critical renewal gift to the Asian Fund for Cancer Research today—and I hope you’ll be as generous as you possibly can. You’ll help us meet our goal to fund the state-of-the-art work of brilliant, passionate cancer researchers who want to beat ALL cancers.
